Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction

  title={Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction},
  author={Hye Sook Min and Jung Eun Kim and Mi Hwa Lee and Hye Kyoung Song and Young Sun Kang and Mi Jin Lee and Ji Eun Lee and Hyun Wook Kim and Jin Joo Cha and Young Yoon Chung and Young Youl Hyun and Jee Young Han and Dae Ryong Cha},
  journal={Laboratory Investigation},
Dipeptidyl peptidase IV (DPPIV) is an exopeptidase that modulates the function of several substrates, among which insulin-releasing incretin hormones are the most well known. DPPIV also modulate substrates involved in inflammation, cell migration, and cell differentiation. Although DPPIV is highly expressed in proximal renal tubular cells, the role of DPPIV inhibition in renal disease is not fully understood. For this reason, we investigated the effects of LC15-0444, a DPPIV inhibitor, on renal… 

Renoprotective effects of a dipeptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis

Alogliptin exerted renoprotective antifibrotic effects and DPP-4 inhibitors may be promising therapeutic choices even for nondiabetic CKD patients, suggesting an anti-inflammatory action by the D PP-4 inhibitor.

Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice

It is demonstrated that evogliptin is protective against UUO-induced renal fibrosis, suggesting that its clinical applications could extend to the treatment of kidney disease of non-diabetic origin.

Inhibition of dipeptidyl peptidase IV protects tacrolimus-induced kidney injury

Data suggest that DPP IV inhibition has an important role in the renoprotection against tacrolimus-induced nephrotoxicity via antioxidative and antiapoptotic effects and preservation of the GLP-1 system.

A Novel Dipeptidyl Peptidase-4 Inhibitor DA-1229 Ameliorates Tubulointerstitial Fibrosis in Cyclosporine Nephrotoxicity in Mice

The results suggest that DPP-4 inhibition by DA-1229 provides renoprotective effects in an animal model of cyclosporine nephrotoxicity via antioxidant, anti-inflammatory, and anti-fibrotic mechanisms.

Glucagon-Like Peptide-1 Mediates the Protective Effect of the Dipeptidyl Peptidase IV Inhibitor on Renal Fibrosis via Reducing the Phenotypic Conversion of Renal Microvascular Cells in Monocrotaline-Treated Rats

It is suggested that DPP-4 inhibition can reduce microcirculation lesion-induced renal fibrosis in a GLP-1-dependent manner.

Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome

The present study shows that activation of the NLRP3 inflammasome contributes to UUO-induced renal fibrosis and the renoprotective effect of gemigliptin is associated with attenuation of NOD-like receptor protein 3 (NLRP3) inflammaome activation.

Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice

It is demonstrated that gemigliptin has renoprotective effects on DKD, regardless of its glucose-lowering effect, suggesting that it could be used to preventDKD, including in patients with type 1 diabetes.

Dipeptidyl peptidase-4 inhibitors in progressive kidney disease

The effects of DPP-4 inhibitors on progressive kidney disease such as diabetic nephropathy is reviewed from a therapeutic point of view and a growing number of studies in animal models and human diseases have shown that D PP-4 inhibition ameliorates kidney disease by a process independent of glucose lowering.



Dipeptidyl Peptidase IV Inhibitor Attenuates Kidney Injury in Streptozotocin-Induced Diabetic Rats

The study suggests that DPP IV inhibitors may ameliorate diabetic nephropathy as well as reduce the overproduction of TGF-β1.

DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury.

Through a mechanism yet to be fully understood, VG treatment results in a functional protection of the kidney against IRI, and was associated with antiapoptotic, immunological, and antioxidative changes.

Effects of DPP-4 Inhibitors on the Heart in a Rat Model of Uremic Cardiomyopathy

DPP-4 inhibition increases plasma GLP-1 levels, particularly in uremia, and reduces expression of cardiac mRNA levels of matrix proteins and B-type natriuretic peptides (BNP), which may offer a unique approach for treating uremic cardiomyopathy in CKD patients, with no need for dose adjustment.

Renal and Cardiac Effects of DPP4 Inhibitors – from Preclinical Development to Clinical Research

The direct cardiac and renal effects seen in preclinical studies as well as meta-analysis of clinical trials may offer additional potentials – beyond improvement of glycemic control - for this newer class of drugs, such as acute kidney failure, chronic kidney failure as as acute myocardial infarction and heart failure.

Involvement of Dipeptidyl Peptidase IV in Immune Complex–Mediated Glomerulonephritis

The results indicate that DPPIV may play a somewhat crucial role in regulating the complement cascade and that inhibition of DPP IV may serve as a new target for preventing complement-dependent tissue injury.

Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat)

Chronic low-dose sitagliptin treatment was able to ameliorate diabetic nephropathy, which might represent a key step forward in the management of T2DM and this serious complication.

Intra-Renal Angiotensin II/AT1 Receptor, Oxidative Stress, Inflammation, and Progressive Injury in Renal Mass Reduction

A link between up-regulation of Ang II/AT1r system and oxidative stress, inflammation, hypertension, and progression of renal disease in rats with renal mass reduction is demonstrated.